Evaluation of a Tailored Patient Navigation Program for Improving Multitarget Stool DNA Test Adherence

评估一项旨在提高多靶点粪便DNA检测依从性的定制化患者导航计划

阅读:2

Abstract

BACKGROUND: Multitarget stool DNA (mt-sDNA) is an increasingly utilized noninvasive option for colorectal cancer screening; however, its impact is limited by imperfect test adherence. Tailored patient navigation (TPN) improves adherence for other cancer screening tests, but its role in mt-sDNA is not known. AIM: Determine whether TPN improves mt-sDNA completion and reduces sample could not be processed (SCNBP) result rates. SETTING: A large, urban, academic primary care clinic serving a medically vulnerable population. PARTICIPANTS: All patients who received mt-sDNA order in 2022 and 2023. PROGRAM DESCRIPTION: A patient navigator outreached all patients ordered mt-sDNA to support test completion during the 12-month intervention period in 2023. PROGRAM EVALUATION: Rates of mt-sDNA completion within 90 days and SCNBP results were compared between the 12-month intervention and pre-intervention periods using generalized estimating equations. A total of 2694 patients received 3297 orders during the study. TPN was significantly associated with improved rates of 90-day mt-sDNA completion (51% vs. 39%, OR 1.67, p < .001) and SCNBP results (4% vs. 5%, OR 0.55, p < .001). DISCUSSION: Tailored patient navigation was associated with improved rates of mt-sDNA completion and SCNBP results despite built-in navigation services provided by the manufacturer. TPN for mt-sDNA is a promising strategy for enhancing colorectal cancer screening uptake.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。